The Retinal Degeneration Fund announces an investment in Amber Bio

Amber Bio is developing a first-of-its-kind RNA writing platform using multi-kilobase edits to reach previously undruggable patient populations RALEIGH, N.C., Aug. 24, 2023 /PRNewswire/ — Today, the RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.